- Home
- CRNC vs AVIR Comparison
CRNC vs AVIR Comparison
Compare CRNC & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRNC | AVIR |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.9M | 434.5M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRNC | AVIR |
|---|---|---|
| Price | $10.31 | $4.46 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $10.25 | $10.00 |
| AVG Volume (30 Days) | ★ 1.0M | 305.3K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.95 | 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | $251,781,000.00 | ★ $351,367,000.00 |
| Revenue This Year | $27.18 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.85 | $2.78 |
| 52 Week High | $13.74 | $6.45 |
Technical Indicators
Market Signals| Indicator | CRNC | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 48.41 | 48.52 |
| Support Level | $9.18 | $4.14 |
| Resistance Level | $11.49 | $4.59 |
| Average True Range (ATR) | 0.80 | 0.18 |
| MACD | -0.16 | 0.04 |
| Stochastic Oscillator | 43.41 | 66.67 |
Price Performance
Historical ComparisonAbout CRNC Cerence Inc.
Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.